Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Xiao, Yi ^a   Yin, Jin ^a   Wei, Jia ^a   Shang, Zhen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ACUTE HEART FAILURE; CANCER PATIENT; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; COMORBIDITY; CONGESTIVE HEART FAILURE; HEART ARREST; HEART ARRHYTHMIA; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE FAILURE; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MORTALITY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HEART DISEASES; HUMANS; INCIDENCE; NEOPLASMS; ODDS RATIO; PYRAZINES; RISK;

EID: 84900416183     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087671     Document Type: Review

References (51)

1. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, et al. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101: 2377-2380. (Pubitemid 36302084)
2. Lu G, Punj V, Chaudhary PM (2008) Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Cancer Biol Ther 7: 603-608. (Pubitemid 351847039)
3. Galimberti S, Canestraro M, Pacini S, Fazzi R, Orciuolo E, et al. (2008) PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells. Leuk Res 32: 103-112. (Pubitemid 350110352)
4. Baiz D, Pozzato G, Dapas B, Farra R, Scaggiante B, et al. (2009) Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie 91: 373-382.
5. Paramore A, Frantz S (2003) Bortezomib. Nat Rev Drug Discov 2: 611-612.
6. Velcade label-accessdata FDA (2008) Available: http://www.accessdata.fda. gov/drugsatfda-docs/label/2008/021602s015lbl.pdf.Accessed 2013 Aug 1.
7. Besse B, Planchard D, Veillard AS, Taillade L, Khayat D, et al. (2012) Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. Lung Cancer 76: 78-83.
8. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498. (Pubitemid 41007864)
9. Enrico O, Gabriele B, Nadia C, Sara G, Daniele V, et al. (2007) Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 138: 396-397. (Pubitemid 47035391)
10. Gupta A, Pandey A, Sethi S (2012) Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma. Cardiovasc Toxicol 12: 184-187.
11. Bockorny M, Chakravarty S, Schulman P, Bockorny B, Bona R (2012) Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature. Acta Haematol 128: 244-247.
12. Takamatsu H, Yamashita T, Kotani T, Sawazaki A, Okumura H, et al. (2010) Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma. Int J Hematol 91: 903-906.
13. Nowis D, Maczewski M, Mackiewicz U, Kujawa M, Ratajska A, et al. (2010) Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 176: 2658-2668.
14. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, et al. (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardiooncological prevention. J Natl Cancer Inst 102: 14-25.
15. Charaf E, Iskandar SB, Blevins A, Abi-Saleh B, Fahrig S (2009) Cardiac amyloidosis responding to bortezomib: case report and review of literature. Curr Cardiol Rev 5: 228-236.
16. Hacihanefioglu A, Tarkun P, Gonullu E (2008) Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol 88: 219-222.
17. Voortman J, Giaccone G (2006) Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer 6: 129.
18. NCI (2006) Cancer Therapy Evaluation Program. CTC v 2.0 and common terminology criteria for adverse events criteria V3.0 (CTCAE). Available: http://ctep.cancer.gov/reporting/ctc.html.
19. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, et al. (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362: 2260-2270.
20. Zintzaras E, Ioannidis JP (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28: 123-137.
21. Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27: 335-371. (Pubitemid 15107153)
22. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
23. Moher DLA, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
24. Hjorth M, Hjertner O, Knudsen LM, Gulbrandsen N, Holmberg E, et al. (2012) Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol 88: 485-496.
25. Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, et al. (2012) Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 30: 2475-2482.
26. Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, et al. (2011) Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118: 5752-5758; quiz 5982.
27. Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, et al. (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 28: 5101-5109.
28. Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, et al. (2010) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11: 934-941.
29. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, et al. (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28: 4621-4629.
30. Dispenzieri A, Jacobus S, Vesole DH, Callandar N, Fonseca R, et al. (2010) Primary therapy with single agent bortezomib as induction, maintenance and reinduction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia 24: 1406-1411.
31. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, et al. (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376: 2075-2085.
32. Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, et al. (2010) Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116: 4745-4753.
33. Popat R, Oakervee H, Williams C, Cook M, Craddock C, et al. (2009) Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol 144: 887-894.
34. Jakubowiak AJ, Kendall T, Al-Zoubi A, Khaled Y, Mineishi S, et al. (2009) Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 27: 5015-5022.
35. Palumbo A, Gay F, Bringhen S, Falcone A, Pescosta N, et al. (2008) Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 19: 1160-1165. (Pubitemid 351796343)
36. Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, et al. (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25: 3892-3901. (Pubitemid 47477266)
37. Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, et al. (2007) Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 138: 330-337. (Pubitemid 47035389)
38. Suvannasankha A, Smith GG, Juliar BE, Abonour R (2006) Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma 7: 131-134. (Pubitemid 44596595)
39. Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, et al. (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108: 2165-2172. (Pubitemid 44497496)
40. Houot R, Le Gouill S, Ojeda Uribe M, Mounier C, Courby S, et al. (2012) Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderlymantle cell lymphoma patients: results of a phase II trial from the GOELAMS. Ann Oncol 23: 1555-1561.
41. Ruan J, Martin P, Furman RR, Lee SM, Cheung K, et al. (2011) Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 29: 690-697.
42. Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, et al. (2011) Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 12: 773-784.
43. Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, et al. (2007) A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 18: 116-121. (Pubitemid 46152510)
44. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, et al. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24: 4867-4874. (Pubitemid 46655613)
45. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, et al. (2006) Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 24: 5025-5033. (Pubitemid 46631406)
46. Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, et al. (2007) Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1570-1575. (Pubitemid 46733084)
47. Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, et al. (2012) An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinumcontaining regimens. Int J Gynecol Cancer 22: 792-800.
48. Chanan-Khan A, Srinivasan S, Czuczman MS (2004) Prevention and management of cardiotoxicity from antineoplastic therapy. J Support Oncol 2: 251-256; discussion 259-261, 264-256.
49. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, et al. (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10: 337.
50. Versari D, Herrmann J, Gossl M, Mannheim D, Sattler K, et al. (2006) Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis. Arterioscler Thromb Vasc Biol 26: 2132-2139. (Pubitemid 44253799)
51. Jancso G, Cserepes B, Gasz B, Benko L, Ferencz A, et al. (2005) Effect of acetylsalicylic acid on nuclear factor-kappaB activation and on late preconditioning against infarction in the myocardium. J Cardiovasc Pharmacol 46: 295-301. (Pubitemid 41262831)